Wolfgang Landgraf

Dr. Wolfgang Landgraf

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in The Lancet
Verified
Journal Article
Closed access
RBReinhard G Bretzel
Reinhard G Bretzel
UNUlrike Nuber
Ulrike Nuber
WLWolfgang Landgraf
Wolfgang Landgraf
DODavid R Owens
David R Owens
CBClare Bradley
Clare Bradley
TLThomas Linn
Thomas Linn

30 April 1992 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
FHFranz Hofmann
Franz Hofmann
WDWolfgang Dostmann
Wolfgang Dostmann
AKAlexandra Keilbach
Alexandra Keilbach
WLWolfgang Landgraf
Wolfgang Landgraf
PRPeter Ruth
Peter Ruth

1 December 1991 in European Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
PRPeter Ruth
Peter Ruth
WLWolfgang Landgraf
Wolfgang Landgraf
AKAlexandra Keilbach
Alexandra Keilbach
BMBoris May
Boris May
CECecile Egleme
Cecile Egleme
FHFranz Hofmann
Franz Hofmann

1 January 1986 in European Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
WLWolfgang Landgraf
Wolfgang Landgraf
RHRoger Hullin
Roger Hullin
CGClaus Gobel
Claus Gobel
FHFranz Hofmann
Franz Hofmann

1 November 2012 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
DODavid R. Owens
David R. Owens
WLWolfgang Landgraf
Wolfgang Landgraf
ASAndrea Schmidt
Andrea Schmidt
RBReinhard G. Bretzel
Reinhard G. Bretzel
MKMartin K. Kuhlmann
Martin K. Kuhlmann
Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture “copies” commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and effective as the conventional products is essential. It is important for the clinician to consider what information is therefore necessary for such assurances. Biopharmaceuticals, produced from living organisms and manufactured by complex processes, differ in many respects from chemically derived drugs. The biological source materials and manufacturing processes for non-innovator biologics may differ considerably from those used for producing the innovator substance. Differences between innovator and non-innovator products can be identified analytically (e.g., batch-to-batch consistency, product stability along side clinical safety). This provides a strong argument for caution before automatic substitution of conventional products (e.g., insulin by biosimilars). Several non-innovator insulins, including insulin analogs (while still patent-protected), are already available in many countries. Many of these lack rigorous regulations for biosimilar approval and pharmacovigilance. Recently an application for a biosimilar recombinant human insulin was withdrawn by the European Medicines Agency because of safety and efficacy concerns. Therefore, every biosimilar insulin and insulin analog should be assessed by well-defined globally harmonized preclinical and clinical studies followed by post-marketing pharmacovigilance programs, in the interest of people with diabetes worldwide.

21 February 2013 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
FPF. Pistrosch
F. Pistrosch
CKC. Köhler
C. Köhler
FSF. Schaper
F. Schaper
WLWolfgang Landgraf
Wolfgang Landgraf
TFT. Forst
T. Forst
MHM. Hanefeld
M. Hanefeld
We investigated whether basal insulin as first-line treatment in recently diagnosed type 2 diabetes (T2D) can improve glucose control, microvascular function and preserve insulin secretion in comparison with metformin (MET). In this open-label, randomized, prospective 36-week study, 75 patients (44 m, 31 f, mean age 60.7 ± 9.2 year) were allocated to treatment with either MET 1,000 mg b.i.d. (n = 36) or insulin glargine (GLA) at bedtime (n = 39). At baseline and study end, we performed a continuous glucose monitoring for assessment of interstitial glucose (IG) and measured microvascular function using Laser-Doppler fluxmetry. GLA versus MET treatment resulted in a more pronounced reduction in FPG (Δ: 3.1 ± 2.5 vs. 1.4 ± 1.5 mmol/l; p < 0.001) and overall IG (Δ AUC. 671 ± 507 vs. 416 ± 537 mmol/l min; p = 0.04). Postprandial PG and IG differences after a standardized test meal did not reach significance. Proinsulin/C-peptide and HOMA B as marker of endogenous insulin secretion were significantly more improved by GLA. Microvascular blood flow improved only in MET-treated patients. Early basal insulin treatment with GLA in T2D patients provided a better control of FPG, overall IG load and biomarker of beta-cell function compared to the standard treatment with MET. MET treatment resulted in an improvement of microvascular function. Studies of longer duration are needed to evaluate the durability of glucose control and β cell protection with early GLA treatment.